DoD awards $11.1B for COVID-19 vaccine production to Pfizer, a sole-source definitive contract

Contract Overview

Contract Amount: $11,110,134,066 ($11.1B)

Contractor: Pfizer Inc

Awarding Agency: Department of Defense

Start Date: 2020-12-22

End Date: 2023-06-30

Contract Duration: 920 days

Daily Burn Rate: $12.1M/day

Competition Type: NOT COMPETED

Number of Offers Received: 1

Pricing Type: FIRM FIXED PRICE

Sector: Healthcare

Official Description: COVID-19 VACCINE PRODUCTION

Place of Performance

Location: NEW YORK, NEW YORK County, NEW YORK, 10017

State: New York Government Spending

Plain-Language Summary

Department of Defense obligated $11.11 billion to PFIZER INC for work described as: COVID-19 VACCINE PRODUCTION Key points: 1. Contract awarded on a sole-source basis, limiting price competition and potentially increasing costs. 2. Significant investment in vaccine production highlights national priority during the pandemic. 3. Long contract duration (920 days) suggests sustained need and production commitment. 4. Firm Fixed Price contract type provides cost certainty for the government. 5. The award represents a substantial portion of federal spending in biological product manufacturing. 6. Geographic concentration in New York for production may present supply chain risks.

Value Assessment

Rating: questionable

Benchmarking the value of this contract is challenging due to its unique nature as a sole-source award for critical pandemic response. However, the substantial dollar amount ($11.1 billion) for vaccine production warrants scrutiny. Without competitive bidding, it's difficult to ascertain if the government secured the best possible price. Comparisons to other large-scale pharmaceutical procurements, especially those with competitive elements, would likely show a higher per-unit cost in this instance.

Cost Per Unit: N/A

Competition Analysis

Competition Level: sole-source

This contract was awarded using a sole-source justification, meaning it was not competed. This approach is typically reserved for situations where only one responsible source can provide the required goods or services. In this case, it likely relates to Pfizer's existing capabilities and intellectual property for their specific COVID-19 vaccine. The lack of competition means the government did not benefit from a bidding process that could drive down prices.

Taxpayer Impact: Taxpayers may have paid a premium due to the absence of competitive pressure. The government's negotiating position was likely weakened without alternative suppliers to consider.

Public Impact

The primary beneficiaries are the American public, receiving access to COVID-19 vaccines. Services delivered include the manufacturing and supply of critical vaccine doses. Geographic impact is national, ensuring vaccine availability across the United States. Workforce implications include jobs in manufacturing, logistics, and related support services at Pfizer facilities.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Sole-source award limits price discovery and potentially inflates costs.
High contract value increases financial risk exposure.
Geographic concentration of production in New York could pose supply chain vulnerabilities.
Long-term commitment may lock government into a specific technology or supplier.

Positive Signals

Addresses a critical national need for pandemic response.
Firm Fixed Price contract provides budget predictability.
Ensures a reliable supply of a vital public health product.

Sector Analysis

The pharmaceutical and biotechnology sector is characterized by high R&D costs, intellectual property protection, and significant regulatory oversight. This contract falls within the biological product manufacturing sub-sector. Federal spending in this area often involves critical public health initiatives, defense readiness, and advanced medical research. Comparable spending benchmarks are difficult to establish for pandemic-specific, sole-source awards of this magnitude.

Small Business Impact

This contract does not appear to involve a small business set-aside. Given the scale and nature of vaccine production, it is unlikely that small businesses would be primary contractors. However, there may be opportunities for small businesses to participate as subcontractors in areas such as logistics, raw material supply, or specialized services, though this is not explicitly detailed in the provided data.

Oversight & Accountability

Oversight for this contract would typically fall under the Department of Defense's contracting and financial management regulations. Accountability measures would include performance monitoring, quality control, and adherence to delivery schedules. Transparency is facilitated through contract databases like FPDS, although the justification for sole-source awards can sometimes limit public understanding of the negotiation process. Inspector General involvement would be triggered by any allegations of fraud, waste, or abuse.

Related Government Programs

COVID-19 Relief Funding
Operation Warp Speed
Department of Health and Human Services (HHS) Vaccine Procurement
Biopharmaceutical Manufacturing Contracts

Risk Flags

Sole-source justification
High contract value
Critical public health product
Long contract duration

Frequently Asked Questions

What is this federal contract paying for?

Department of Defense awarded $11.11 billion to PFIZER INC. COVID-19 VACCINE PRODUCTION

Who is the contractor on this award?

The obligated recipient is PFIZER INC.

Which agency awarded this contract?

Awarding agency: Department of Defense (Department of the Army).

What is the total obligated amount?

The obligated amount is $11.11 billion.

What is the period of performance?

Start: 2020-12-22. End: 2023-06-30.

What is Pfizer's track record with large government contracts, particularly in vaccine development and production?

Pfizer has a long history of working with government agencies, including the Department of Defense and the Department of Health and Human Services, on various pharmaceutical and vaccine-related initiatives. They have been a significant player in vaccine development and manufacturing for decades, producing vaccines for diseases like influenza and pneumococcal disease. Their experience extends to navigating complex regulatory pathways and scaling up production for public health needs. While specific details on past large-scale sole-source vaccine contracts are not readily available, their established presence and capabilities in the biopharmaceutical industry suggest a capacity to handle substantial government orders. However, the scale and urgency of the COVID-19 pandemic presented unique challenges and required unprecedented government investment and support.

How does the $11.1 billion award compare to typical federal spending on vaccine production?

The $11.1 billion awarded to Pfizer for COVID-19 vaccine production is exceptionally high compared to typical federal spending on vaccine manufacturing. Historically, federal investments in vaccine production have been spread across multiple programs, diseases, and manufacturers, often through competitive contracts or research grants. Large, single-source awards of this magnitude are rare and usually reserved for national emergencies or critical defense needs. This figure likely reflects the unprecedented scale of the pandemic, the urgency required, and the sole-source nature of the award, which bypasses competitive bidding processes that might otherwise distribute the investment across a broader market or secure lower unit prices.

What are the primary risks associated with a sole-source contract of this size for vaccine production?

The primary risks associated with a sole-source contract of this magnitude include a lack of price competition, which can lead to higher costs for the government and taxpayers. There's also the risk of vendor lock-in, where the government becomes dependent on a single supplier, potentially limiting flexibility if alternative or improved technologies emerge. Furthermore, a sole-source award can reduce transparency in the procurement process, making it harder to justify the value received. Supply chain disruptions or production issues at the single vendor's facilities could have a disproportionately large impact on national vaccine availability. Finally, without competitive pressure, there might be less incentive for the contractor to innovate or optimize production efficiency beyond contractual requirements.

How effective has this contract been in ensuring the supply of COVID-19 vaccines?

This contract has been instrumental in ensuring a substantial supply of COVID-19 vaccines for the United States. As a sole-source award to a major manufacturer, it provided the necessary funding and commitment to rapidly scale up production capabilities. The firm fixed-price nature of the contract offered predictability for both parties, facilitating large-scale manufacturing operations. While specific effectiveness metrics like 'vaccines delivered per dollar' are complex to isolate due to the dynamic nature of the pandemic and evolving public health guidance, the sheer volume of vaccines produced under such agreements has been critical to the national vaccination effort, contributing significantly to public health outcomes and the mitigation of the pandemic's impact.

What are the historical spending patterns for biological product manufacturing by the Department of Defense?

The Department of Defense (DoD) historically spends on biological product manufacturing primarily for readiness and medical countermeasures, rather than widespread public health initiatives like civilian vaccine distribution. Spending typically focuses on vaccines for military personnel (e.g., anthrax, smallpox), therapeutic agents, and research and development into new biological defenses. While the DoD does engage in large-scale procurements, spending specifically on 'Biological Product (except Diagnostic) Manufacturing' (NAICS 325414) can fluctuate significantly year-to-year based on specific threats, research breakthroughs, and stockpiling requirements. The $11.1 billion for COVID-19 vaccines represents an extraordinary surge, far exceeding typical annual spending in this category, driven by the unique circumstances of the pandemic and a directive to support national public health.

Industry Classification

NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › Biological Product (except Diagnostic) Manufacturing

Product/Service Code: MEDICAL/DENTAL/VETERINARY EQPT/SUPP

Competition & Pricing

Extent Competed: NOT COMPETED

Solicitation Procedures: ONLY ONE SOURCE

Solicitation ID: W15QKN21R0038

Offers Received: 1

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Address: 235 E 42ND ST, NEW YORK, NY, 10017

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Manufacturer of Goods, Not Designated a Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $11,285,134,066

Exercised Options: $11,110,134,066

Current Obligation: $11,110,134,066

Actual Outlays: $113,075,858

Contract Characteristics

Commercial Item: COMMERCIAL PRODUCTS/SERVICES

Cost or Pricing Data: NO

Timeline